Answers are grounded in this paper and cite their sources.
Shows panitumumab improves progression-free survival in chemotherapy-refractory colorectal cancer, suggesting its potential as a treatment option.
Panitumumab significantly improved PFS with manageable toxicity in patients with chemorefractory colorectal cancer.
No takes yet. Share an insight, caveat, or question.
Cutsem et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: